Loading…
Lobbying Spend
—
Filings
51
Firms Hired
1
Active Period
1999–2017
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
H.R. 34, 21st Century Cures ACT; Drug safety and drug counterfeiting; Drug importation; 340B Program; Authorized generics; Drug company patent settlements; Senate Finance Committee Chronic Disease Initiative; Implementation of Precision Medicine Initiative; White House Cancer Moonshot; Legislation affecting the ESRD program.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 34
Establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025.
2015 · second_quarter · Firm: WILLIAMS AND JENSEN, PLLC
21st Century Cures Initiative (House Energy and Commerece Committee) and Innovations for Healthier Americans (Senate Health, Education, Labor and Pensions Committee); potential pharmaceutical provisions in House Budget Resolution (H. Con. Res. 27) and Senate Budget Resolution (S. Con. Res. 11); Possible drug provisions in H.R. 2, the Medicare Access and CHIP Reauthorization Act; Drug safety and drug counterfeiting; Drug importation; 340B Program; Authorized generics; Drug company patent settlements; Prescription drug advertising; Federal preemption for prescription drugs; Drug shortages.
Client expense: — · Firm income: $50,000
Matched citations: H. Con. Res. 27
Medicare Access and CHIP Reauthorization Act of 2015
2015 · second_quarter · Firm: WILLIAMS AND JENSEN, PLLC
21st Century Cures Initiative (House Energy and Commerece Committee) and Innovations for Healthier Americans (Senate Health, Education, Labor and Pensions Committee); potential pharmaceutical provisions in House Budget Resolution (H. Con. Res. 27) and Senate Budget Resolution (S. Con. Res. 11); Possible drug provisions in H.R. 2, the Medicare Access and CHIP Reauthorization Act; Drug safety and drug counterfeiting; Drug importation; 340B Program; Authorized generics; Drug company patent settlements; Prescription drug advertising; Federal preemption for prescription drugs; Drug shortages.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 2
An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025.
2015 · second_quarter · Firm: WILLIAMS AND JENSEN, PLLC
21st Century Cures Initiative (House Energy and Commerece Committee) and Innovations for Healthier Americans (Senate Health, Education, Labor and Pensions Committee); potential pharmaceutical provisions in House Budget Resolution (H. Con. Res. 27) and Senate Budget Resolution (S. Con. Res. 11); Possible drug provisions in H.R. 2, the Medicare Access and CHIP Reauthorization Act; Drug safety and drug counterfeiting; Drug importation; 340B Program; Authorized generics; Drug company patent settlements; Prescription drug advertising; Federal preemption for prescription drugs; Drug shortages.
Client expense: — · Firm income: $50,000
Matched citations: S. Con. Res. 11
Establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025.
2015 · first_quarter · Firm: WILLIAMS AND JENSEN, PLLC
21st Century Cures Initiative (House Energy and Commerece Committee) and Innovations for Healthier Americans (Senate Health, Education, Labor and Pensions Committee); potential pharmaceutical provisions in House Budget Resolution (H. Con. Res. 27) and Senate Budget Resolution (S. Con. Res. 11); Possible drug provisions in H.R. 2, the Medicare Access and CHIP Reauthorization Act; Drug safety and drug counterfeiting; Drug importation; 340B Program; Authorized generics; Drug company patent settlements; Prescription drug advertising; Federal preemption for prescription drugs; Drug shortages.
Client expense: — · Firm income: $50,000
Matched citations: H. Con. Res. 27
Medicare Access and CHIP Reauthorization Act of 2015
2015 · first_quarter · Firm: WILLIAMS AND JENSEN, PLLC
21st Century Cures Initiative (House Energy and Commerece Committee) and Innovations for Healthier Americans (Senate Health, Education, Labor and Pensions Committee); potential pharmaceutical provisions in House Budget Resolution (H. Con. Res. 27) and Senate Budget Resolution (S. Con. Res. 11); Possible drug provisions in H.R. 2, the Medicare Access and CHIP Reauthorization Act; Drug safety and drug counterfeiting; Drug importation; 340B Program; Authorized generics; Drug company patent settlements; Prescription drug advertising; Federal preemption for prescription drugs; Drug shortages.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 2
An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025.
2015 · first_quarter · Firm: WILLIAMS AND JENSEN, PLLC
21st Century Cures Initiative (House Energy and Commerece Committee) and Innovations for Healthier Americans (Senate Health, Education, Labor and Pensions Committee); potential pharmaceutical provisions in House Budget Resolution (H. Con. Res. 27) and Senate Budget Resolution (S. Con. Res. 11); Possible drug provisions in H.R. 2, the Medicare Access and CHIP Reauthorization Act; Drug safety and drug counterfeiting; Drug importation; 340B Program; Authorized generics; Drug company patent settlements; Prescription drug advertising; Federal preemption for prescription drugs; Drug shortages.
Client expense: — · Firm income: $50,000
Matched citations: S. Con. Res. 11
Proposing an amendment to the Constitution of the United States to protect the rights of crime victims.
2013 · fourth_quarter · Firm: WILLIAMS AND JENSEN, PLLC
Medicare prescription drug benefit. Drug rebates for Medicare Part D. Part D benefit structure. Indpendent Payment Advisory Board (IPAB). House and Senate action on H.J. Res. 59 and possible drug industry issues.
Client expense: — · Firm income: $80,000
Matched citations: H.J. Res. 59
To amend the Small Business Act to provide for an increase in the amount of awards under the first and second phases of the Small Business Innovation Research program.
2010 · fourth_quarter · Firm: WILLIAMS AND JENSEN, PLLC
Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; 340 B Program including H.R. 4213, American Jobs and Closing Tax Loopholes Act; Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act; Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act, and FY 2011 Financial Services and General Government Appropriations bill; Stem cell research including S. 487/H.R. 873, Stem Cell Research Enhancement Act of 2009; Prescription drug advertising; Federal preemption for prescription drugs; and Legislation concerning civil litigation including S. 357, Sunshine in Litigation Act of 2009.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 4213
Pharmaceutical Market Access and Drug Safety Act of 2009
2010 · fourth_quarter · Firm: WILLIAMS AND JENSEN, PLLC
Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; 340 B Program including H.R. 4213, American Jobs and Closing Tax Loopholes Act; Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act; Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act, and FY 2011 Financial Services and General Government Appropriations bill; Stem cell research including S. 487/H.R. 873, Stem Cell Research Enhancement Act of 2009; Prescription drug advertising; Federal preemption for prescription drugs; and Legislation concerning civil litigation including S. 357, Sunshine in Litigation Act of 2009.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 1298
Protecting Consumer Access to Generic Drugs Act of 2009
2010 · fourth_quarter · Firm: WILLIAMS AND JENSEN, PLLC
Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; 340 B Program including H.R. 4213, American Jobs and Closing Tax Loopholes Act; Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act; Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act, and FY 2011 Financial Services and General Government Appropriations bill; Stem cell research including S. 487/H.R. 873, Stem Cell Research Enhancement Act of 2009; Prescription drug advertising; Federal preemption for prescription drugs; and Legislation concerning civil litigation including S. 357, Sunshine in Litigation Act of 2009.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 1706
To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs.
2010 · fourth_quarter · Firm: WILLIAMS AND JENSEN, PLLC
Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; 340 B Program including H.R. 4213, American Jobs and Closing Tax Loopholes Act; Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act; Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act, and FY 2011 Financial Services and General Government Appropriations bill; Stem cell research including S. 487/H.R. 873, Stem Cell Research Enhancement Act of 2009; Prescription drug advertising; Federal preemption for prescription drugs; and Legislation concerning civil litigation including S. 357, Sunshine in Litigation Act of 2009.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 573
School Building Enhancement Act
2010 · fourth_quarter · Firm: WILLIAMS AND JENSEN, PLLC
Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; 340 B Program including H.R. 4213, American Jobs and Closing Tax Loopholes Act; Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act; Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act, and FY 2011 Financial Services and General Government Appropriations bill; Stem cell research including S. 487/H.R. 873, Stem Cell Research Enhancement Act of 2009; Prescription drug advertising; Federal preemption for prescription drugs; and Legislation concerning civil litigation including S. 357, Sunshine in Litigation Act of 2009.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 579
Stem Cell Research Enhancement Act of 2009
2010 · fourth_quarter · Firm: WILLIAMS AND JENSEN, PLLC
Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; 340 B Program including H.R. 4213, American Jobs and Closing Tax Loopholes Act; Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act; Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act, and FY 2011 Financial Services and General Government Appropriations bill; Stem cell research including S. 487/H.R. 873, Stem Cell Research Enhancement Act of 2009; Prescription drug advertising; Federal preemption for prescription drugs; and Legislation concerning civil litigation including S. 357, Sunshine in Litigation Act of 2009.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 873
Pharmaceutical Market Access and Drug Safety Act of 2009
2010 · fourth_quarter · Firm: WILLIAMS AND JENSEN, PLLC
Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; 340 B Program including H.R. 4213, American Jobs and Closing Tax Loopholes Act; Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act; Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act, and FY 2011 Financial Services and General Government Appropriations bill; Stem cell research including S. 487/H.R. 873, Stem Cell Research Enhancement Act of 2009; Prescription drug advertising; Federal preemption for prescription drugs; and Legislation concerning civil litigation including S. 357, Sunshine in Litigation Act of 2009.
Client expense: — · Firm income: $50,000
Matched citations: S. 1232
Equal Justice for United States Military Personnel Act of 2009
2010 · fourth_quarter · Firm: WILLIAMS AND JENSEN, PLLC
Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; 340 B Program including H.R. 4213, American Jobs and Closing Tax Loopholes Act; Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act; Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act, and FY 2011 Financial Services and General Government Appropriations bill; Stem cell research including S. 487/H.R. 873, Stem Cell Research Enhancement Act of 2009; Prescription drug advertising; Federal preemption for prescription drugs; and Legislation concerning civil litigation including S. 357, Sunshine in Litigation Act of 2009.
Client expense: — · Firm income: $50,000
Matched citations: S. 357
Preserve Access to Affordable Generics Act
2010 · fourth_quarter · Firm: WILLIAMS AND JENSEN, PLLC
Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; 340 B Program including H.R. 4213, American Jobs and Closing Tax Loopholes Act; Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act; Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act, and FY 2011 Financial Services and General Government Appropriations bill; Stem cell research including S. 487/H.R. 873, Stem Cell Research Enhancement Act of 2009; Prescription drug advertising; Federal preemption for prescription drugs; and Legislation concerning civil litigation including S. 357, Sunshine in Litigation Act of 2009.
Client expense: — · Firm income: $50,000
Matched citations: S. 369
Stem Cell Research Enhancement Act of 2009
2010 · fourth_quarter · Firm: WILLIAMS AND JENSEN, PLLC
Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; 340 B Program including H.R. 4213, American Jobs and Closing Tax Loopholes Act; Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act; Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act, and FY 2011 Financial Services and General Government Appropriations bill; Stem cell research including S. 487/H.R. 873, Stem Cell Research Enhancement Act of 2009; Prescription drug advertising; Federal preemption for prescription drugs; and Legislation concerning civil litigation including S. 357, Sunshine in Litigation Act of 2009.
Client expense: — · Firm income: $50,000
Matched citations: S. 487
Fair Prescription Drug Competition Act
2010 · fourth_quarter · Firm: WILLIAMS AND JENSEN, PLLC
Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; 340 B Program including H.R. 4213, American Jobs and Closing Tax Loopholes Act; Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act; Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act, and FY 2011 Financial Services and General Government Appropriations bill; Stem cell research including S. 487/H.R. 873, Stem Cell Research Enhancement Act of 2009; Prescription drug advertising; Federal preemption for prescription drugs; and Legislation concerning civil litigation including S. 357, Sunshine in Litigation Act of 2009.
Client expense: — · Firm income: $50,000
Matched citations: S. 501
Pharmaceutical Market Access and Drug Safety Act of 2009
2010 · fourth_quarter · Firm: WILLIAMS AND JENSEN, PLLC
Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; 340 B Program including H.R. 4213, American Jobs and Closing Tax Loopholes Act; Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act; Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act, and FY 2011 Financial Services and General Government Appropriations bill; Stem cell research including S. 487/H.R. 873, Stem Cell Research Enhancement Act of 2009; Prescription drug advertising; Federal preemption for prescription drugs; and Legislation concerning civil litigation including S. 357, Sunshine in Litigation Act of 2009.
Client expense: — · Firm income: $50,000
Matched citations: S. 525
To amend the Small Business Act to provide for an increase in the amount of awards under the first and second phases of the Small Business Innovation Research program.
2010 · third_quarter · Firm: WILLIAMS AND JENSEN, PLLC
Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; 340 B Program including H.R. 4213, American Jobs and Closing Tax Loopholes Act; Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act; Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act, and FY 2011 Financial Services and General Government Appropriations bill; Stem cell research including S. 487/H.R. 873, Stem Cell Research Enhancement Act of 2009; Prescription drug advertising; Federal preemption for prescription drugs; and Legislation concerning civil litigation including S. 357, Sunshine in Litigation Act of 2009.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 4213
Pharmaceutical Market Access and Drug Safety Act of 2009
2010 · third_quarter · Firm: WILLIAMS AND JENSEN, PLLC
Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; 340 B Program including H.R. 4213, American Jobs and Closing Tax Loopholes Act; Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act; Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act, and FY 2011 Financial Services and General Government Appropriations bill; Stem cell research including S. 487/H.R. 873, Stem Cell Research Enhancement Act of 2009; Prescription drug advertising; Federal preemption for prescription drugs; and Legislation concerning civil litigation including S. 357, Sunshine in Litigation Act of 2009.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 1298
Protecting Consumer Access to Generic Drugs Act of 2009
2010 · third_quarter · Firm: WILLIAMS AND JENSEN, PLLC
Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; 340 B Program including H.R. 4213, American Jobs and Closing Tax Loopholes Act; Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act; Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act, and FY 2011 Financial Services and General Government Appropriations bill; Stem cell research including S. 487/H.R. 873, Stem Cell Research Enhancement Act of 2009; Prescription drug advertising; Federal preemption for prescription drugs; and Legislation concerning civil litigation including S. 357, Sunshine in Litigation Act of 2009.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 1706
To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs.
2010 · third_quarter · Firm: WILLIAMS AND JENSEN, PLLC
Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; 340 B Program including H.R. 4213, American Jobs and Closing Tax Loopholes Act; Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act; Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act, and FY 2011 Financial Services and General Government Appropriations bill; Stem cell research including S. 487/H.R. 873, Stem Cell Research Enhancement Act of 2009; Prescription drug advertising; Federal preemption for prescription drugs; and Legislation concerning civil litigation including S. 357, Sunshine in Litigation Act of 2009.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 573
School Building Enhancement Act
2010 · third_quarter · Firm: WILLIAMS AND JENSEN, PLLC
Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; 340 B Program including H.R. 4213, American Jobs and Closing Tax Loopholes Act; Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act; Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act, and FY 2011 Financial Services and General Government Appropriations bill; Stem cell research including S. 487/H.R. 873, Stem Cell Research Enhancement Act of 2009; Prescription drug advertising; Federal preemption for prescription drugs; and Legislation concerning civil litigation including S. 357, Sunshine in Litigation Act of 2009.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 579
Source: Senate LDA